Key Points
- RA Capital Management bought 479,039 Artiva Biotherapeutics shares on June 9 at an average of $6.91 each, spending about $3.31 million. After the purchase, it held 15.68 million shares valued at roughly $108.37 million.
- RA Capital also made additional recent buys, including 548,580 shares on June 11 and a much larger 6.51 million-share purchase on May 11, signaling continued accumulation of the stock.
- Artiva Biotherapeutics trades around $8.00, has a 52-week range of $1.47 to $14.53, and recently reported a quarterly loss of $0.95 per share, slightly worse than analyst expectations.
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) Director Ra Capital Management, L.P. bought 479,039 shares of the business's stock in a transaction that occurred on Tuesday, June 9th. The shares were bought at an average cost of $6.91 per share, for a total transaction of $3,310,159.49. Following the completion of the purchase, the director owned 15,683,034 shares of the company's stock, valued at $108,369,764.94. This represents a 3.15% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Ra Capital Management, L.P. also recently made the following trade(s):
- On Thursday, June 11th, Ra Capital Management, L.P. bought 548,580 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $7.91 per share, for a total transaction of $4,339,267.80.
- On Wednesday, June 10th, Ra Capital Management, L.P. acquired 103 shares of Artiva Biotherapeutics stock. The shares were purchased at an average price of $7.00 per share, with a total value of $721.00.
- On Monday, May 11th, Ra Capital Management, L.P. purchased 6,510,416 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $11.52 per share, for a total transaction of $74,999,992.32.
Artiva Biotherapeutics Price Performance
NASDAQ ARTV opened at $8.00 on Friday. Artiva Biotherapeutics, Inc. has a 1 year low of $1.47 and a 1 year high of $14.53. The firm has a market cap of $197.76 million, a price-to-earnings ratio of -2.26 and a beta of 2.38. The company has a fifty day moving average price of $8.89 and a 200-day moving average price of $6.12.
Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last released its earnings results on Friday, May 8th. The company reported ($0.95) earnings per share for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.07). On average, research analysts anticipate that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current fiscal year.
Hedge Funds Weigh In On Artiva Biotherapeutics
Several large investors have recently made changes to their positions in the company. Citadel Advisors LLC grew its holdings in Artiva Biotherapeutics by 419.3% in the third quarter. Citadel Advisors LLC now owns 798,397 shares of the company's stock valued at $2,291,000 after purchasing an additional 644,658 shares during the period. BNP Paribas Financial Markets grew its holdings in Artiva Biotherapeutics by 14,463.5% in the third quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company's stock valued at $340,000 after purchasing an additional 117,733 shares during the period. Renaissance Technologies LLC grew its holdings in Artiva Biotherapeutics by 46.8% in the fourth quarter. Renaissance Technologies LLC now owns 116,200 shares of the company's stock valued at $498,000 after purchasing an additional 37,053 shares during the period. Marshall Wace LLP acquired a new stake in Artiva Biotherapeutics in the fourth quarter valued at approximately $341,000. Finally, Jane Street Group LLC acquired a new position in shares of Artiva Biotherapeutics during the 2nd quarter worth about $67,000.
Wall Street Analysts Forecast Growth
ARTV has been the subject of several recent research reports. Needham & Company LLC reissued a "buy" rating and set a $41.00 price objective on shares of Artiva Biotherapeutics in a research report on Monday. Wall Street Zen downgraded shares of Artiva Biotherapeutics from a "hold" rating to a "sell" rating in a report on Sunday, May 17th. Weiss Ratings restated a "sell (d-)" rating on shares of Artiva Biotherapeutics in a research report on Friday, April 24th. HC Wainwright upped their price target on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a "buy" rating in a report on Friday, May 8th. Finally, Wedbush raised their price target on Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an "outperform" rating in a research note on Monday, May 11th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $39.00.
View Our Latest Research Report on Artiva Biotherapeutics
About Artiva Biotherapeutics
(
Get Free Report)
Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company's proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.
Artiva's pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
